Leap Therapeutics Reports Second Quarter 2022 Financial Results

/PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...

Related Keywords

Australia ,Japan ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,New Zealand ,Texas ,Australian ,American ,Matthew Deyoung ,Douglase Onsi ,American Society Of Clinical Oncology ,Prnewswire Leap Therapeutics Inc ,Securities Exchange ,Beigene Ltd ,Leap Therapeutics Inc ,Nasdaq ,University Of Alabama At Birmingham ,Cancer Center ,Clinical Oncology ,Chief Executive Officer ,Beigene Announced Initiation ,Ongoing Distinguish Study ,Announced Initiation ,Defiance Study ,Second Line Patients ,Investigator Initiated Trial ,Endometrial Cancer ,Presented Initial Clinical Data ,Investigator Sponsored Study ,Prostate Cancer ,Second Quarter ,Leap Therapeutics ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Leap Therapeutic ,Annual Report ,Quarterly Reports ,Consolidated Statements ,Months Ended June ,Stockholder Equity ,Cash Flows ,Nc ,